(NASDAQ: APLS) Apellis Pharmaceuticals's forecast annual revenue growth rate of 19.86% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.66%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.63%.
Apellis Pharmaceuticals's revenue in 2025 is $715,217,000.On average, 11 Wall Street analysts forecast APLS's revenue for 2025 to be $106,121,299,912, with the lowest APLS revenue forecast at $96,198,095,767, and the highest APLS revenue forecast at $125,131,911,521. On average, 9 Wall Street analysts forecast APLS's revenue for 2026 to be $128,567,273,471, with the lowest APLS revenue forecast at $110,747,103,035, and the highest APLS revenue forecast at $155,239,997,356.
In 2027, APLS is forecast to generate $153,872,918,099 in revenue, with the lowest revenue forecast at $132,801,984,949 and the highest revenue forecast at $177,614,569,323.